Quetiapine - AstraZeneca

Drug Profile

Quetiapine - AstraZeneca

Alternative Names: FK 949; FK949E; ICI 204636; Quetiapine extended release; Quetiapine fumarate; Quetiapine prolonged release; Seroquel; Seroquel XL; Seroquel XR

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer Astellas Pharma; AstraZeneca; Hutchison MediPharma
  • Class Analgesics; Antipsychotics; Dibenzothiazepines; Mood stabilisers; Piperazines; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Alpha 2 adrenergic receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar depression; Bipolar disorders; Major depressive disorder; Manic episodes; Schizophrenia
  • Phase III Borderline personality disorders
  • Preregistration Submission Withdrawal Generalised anxiety disorder
  • No development reported Delirium; Irritable bowel syndrome
  • Discontinued Alcoholism; Behavioural disorders; Psychotic disorders

Most Recent Events

  • 31 Jul 2017 Registered for Bipolar disorders in Japan (PO) (Astellas pipeline, July 2017)
  • 01 Nov 2016 First Generic equivalent for SEROQUEL XR® launched in USA
  • 31 Aug 2016 Preregistration for Bipolar disorders in Japan (PO) (Astellas pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top